4//SEC Filing
Flynn Daniel Lee 4
Accession 0001209191-21-012115
CIK 0001654151other
Filed
Feb 17, 7:00 PM ET
Accepted
Feb 18, 7:00 PM ET
Size
11.0 KB
Accession
0001209191-21-012115
Insider Transaction Report
Form 4
Flynn Daniel Lee
Chief Scientific Officer
Transactions
- Sale
Common Stock
2021-02-16$48.87/sh−508$24,826→ 6,532 total - Award
Common Stock
2021-02-16+11,100→ 17,632 total - Award
Stock Option (Right to Buy)
2021-02-16+49,900→ 49,900 totalExercise: $47.79Exp: 2031-02-15→ Common Stock (49,900 underlying)
Holdings
- 230,435(indirect: By Trust)
Common Stock
- 91,020(indirect: By Trust)
Common Stock
Footnotes (4)
- [F1]The sale was to cover tax liabilities in the vesting of restricted stock.
- [F2]Excludes 230,435 shares previously owned directly by the reporting person which were contributed to the Daniel L. Flynn Revocable Trust on January 15, 2021.
- [F3]The reporting person was awarded 11,100 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's Common Stock. The Restricted Stock Units shall vest in equal 25% installments on February 15, 2022, February 15, 2023, February 15, 2024 and February 15, 2025. The Restricted Stock Units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
- [F4]This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four years, beginning on March 16, 2021.
Documents
Issuer
Deciphera Pharmaceuticals, Inc.
CIK 0001654151
Entity typeother
Related Parties
1- filerCIK 0001713712
Filing Metadata
- Form type
- 4
- Filed
- Feb 17, 7:00 PM ET
- Accepted
- Feb 18, 7:00 PM ET
- Size
- 11.0 KB